USTRx Act

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 4780 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 4780 To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES July 29, 2025 Mr. Arrington (for himself, Mr. Buchanan, Mr. Fleischmann, Ms. Tenney, and Mr. Murphy) introduced the following bill; which was referred to the Committee on Ways and Means _______________________________________________________________________ A BILL To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Use Sovereignty To reduce Rx Act'' or the ``USTRx Act''. SEC. 2. FINDINGS; SENSE OF CONGRESS. (a) Findings.--Congress finds the following: (1) Pharmaceutical price controls in foreign markets distort global trade flows and competition by depressing the prices of innovative drugs and exploiting pharmaceutical innovations researched and developed in the United States. (2) By setting prices at levels that are not market-based, such price controls undervalue the discovery of new, innovative treatments, diminish opportunities and incentives for global innovation in new medicines, and threaten to restrict access to new treatments and cures for United States patients and consumers. (3) Recognizing these dynamics, it is critical that the United States use all available trade tools to address such free-riding to ensure that fore